Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Clinical Trial to Evaluate the Efficacy and Safety of VV913 Capsules in the Treatment of Premature Ejaculation

NCT07722780 is registered in ClinicalTrials.gov with Vigonvita Life Sciences as lead sponsor.

NCT NCT07722780
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07722780 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Clinical Trial to Evaluate the Efficacy and Safety of VV913 Capsules in the Treatment of Premature Ejaculation
Lead sponsor
Vigonvita Life Sciences
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
December 31, 2027
Enrollment
500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

premature ejaculation